Skip to main content

Table 2 PI3KCA mutations and PTEN loss in Chinese GC

From: The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

Mutation Assay Status (%)
PI3KCA (hot spots) ASPCR 2.7% (4/150)
PTEN loss IHC 23% (14/61)